<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39376996</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2162-2531</ISSN><JournalIssue CitedMedium="Print"><Volume>35</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>10</Day></PubDate></JournalIssue><Title>Molecular therapy. Nucleic acids</Title><ISOAbbreviation>Mol Ther Nucleic Acids</ISOAbbreviation></Journal><ArticleTitle>Inhibition of SARS-CoV-2 growth in the lungs of mice by a peptide-conjugated morpholino oligomer targeting viral RNA.</ArticleTitle><Pagination><StartPage>102331</StartPage><MedlinePgn>102331</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">102331</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.omtn.2024.102331</ELocationID><Abstract><AbstractText>Further development of direct-acting antiviral agents against human SARS-CoV-2 infections remains a public health priority. Here, we report that an antisense peptide-conjugated morpholino oligomer (PPMO) named 5'END-2, targeting a highly conserved sequence in the 5' UTR of SARS-CoV-2 genomic RNA, potently suppressed SARS-CoV-2 growth <i>in vitro</i> and <i>in vivo</i>. In HeLa-ACE 2 cells, 5'END-2 produced IC<sub>50</sub> values of between 40 nM and 1.15 μM in challenges using six genetically disparate strains of SARS-CoV-2, including JN.1. <i>In vivo</i>, using K18-hACE2 mice and the WA-1/2020 virus isolate, two doses of 5'END-2 at 10 mg/kg, administered intranasally on the day before and the day after infection, produced approximately 1.4 log10 virus titer reduction in lung tissue at 3 days post-infection. Under a similar dosing schedule, intratracheal administration of 1.0-2.0 mg/kg 5'END-2 produced over 3.5 log10 virus growth suppression in mouse lungs. Electrophoretic mobility shift assays characterized specific binding of 5'END-2 to its complementary target RNA. Furthermore, using reporter constructs containing SARS-CoV-2 5' UTR leader sequence, in an in-cell system, we observed that 5'END-2 could interfere with translation in a sequence-specific manner. The results demonstrate that direct pulmonary delivery of 5'END-2 PPMO is a promising antiviral strategy against SARS-CoV-2 infections and warrants further development.</AbstractText><CopyrightInformation>© 2024 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sakai</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Scripps Research Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Gagandeep</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khoshbakht</LastName><ForeName>Mahsa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Carlson College of Veterinary Medicine, Oregon State University, Corvallis, OR 97331, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bittner</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Carlson College of Veterinary Medicine, Oregon State University, Corvallis, OR 97331, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Löhr</LastName><ForeName>Christiane V</ForeName><Initials>CV</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Carlson College of Veterinary Medicine, Oregon State University, Corvallis, OR 97331, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaz-Tapia</LastName><ForeName>Randy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warang</LastName><ForeName>Prajakta</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Kris</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Luke Le</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Case Western Reserve University, Cleveland, OH 44106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tolbert</LastName><ForeName>Blanton</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Case Western Reserve University, Cleveland, OH 44106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blanco</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Biology, California Institute of Technology, Pasadena, CA 91125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Biology, California Institute of Technology, Pasadena, CA 91125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guttman</LastName><ForeName>Mitchell</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Biology, California Institute of Technology, Pasadena, CA 91125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Cuiping</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>National Genomics Data Center, China National Center for Bioinformation, Beijing 100101, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bao</LastName><ForeName>Yiming</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Genomics Data Center, China National Center for Bioinformation, Beijing 100101, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing 100049, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Joses</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>GISAID @ A∗STAR Bioinformatics Institute, Singapore 138632, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maurer-Stroh</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>GISAID @ A∗STAR Bioinformatics Institute, Singapore 138632, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chatterjee</LastName><ForeName>Arnab</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Scripps Research Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chanda</LastName><ForeName>Sumit</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Scripps Research Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>García-Sastre</LastName><ForeName>Adolfo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Molecular, and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schotsaert</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teijaro</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Scripps Research Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moulton</LastName><ForeName>Hong M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Carlson College of Veterinary Medicine, Oregon State University, Corvallis, OR 97331, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stein</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Carlson College of Veterinary Medicine, Oregon State University, Corvallis, OR 97331, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Ther Nucleic Acids</MedlineTA><NlmUniqueID>101581621</NlmUniqueID><ISSNLinking>2162-2531</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">K-18-hACE2 mouse model</Keyword><Keyword MajorTopicYN="N">MT: Oligonucleotides: Therapies and Applications</Keyword><Keyword MajorTopicYN="N">PPMO</Keyword><Keyword MajorTopicYN="N">RNA virus</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antisense</Keyword><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">intranasal delivery</Keyword><Keyword MajorTopicYN="N">intratracheal delivery</Keyword><Keyword MajorTopicYN="N">peptide-conjugated morpholino oligomer</Keyword></KeywordList><CoiStatement>D.A.S. and H.M.M are listed as inventors on a US patent application, which includes a PPMO developed in this study, filed by Oregon State University. The H.M.M. laboratory has received research support from Radiation Control Technology, BriSight Biosciences, and Autoimmunity BioSolutions. The A.G.-S. laboratory has received research support from GSK, Pfizer, Senhwa Biosciences, Kenall Manufacturing, Blade Therapeutics, Avimex, Johnson &amp; Johnson, Dynavax, 7 Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N-fold LLC, Model Medicines, Atea Pharma, Applied Biological Laboratories, and Merck outside of the reported work. A.G.-S. has consulting agreements with the following companies involving cash and/or stock: Castlevax, Amovir, Vivaldi Biosciences, Contrafect, 7 Hills Pharma, Avimex, Pagoda, Accurius, Esperovax, Applied Biological Laboratories, Pharmamar, CureLab Oncology, CureLab Veterinary, Synairgen, Paratus, Pfizer, and Prosetta outside of the reported work. A.G.-S. has been an invited speaker in meeting events organized by Seqirus, Janssen, Abbott and Astrazeneca. A.G.-S. is listed as an inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections and cancer, owned by the Icahn School of Medicine at Mount Sinai, New York, outside of the reported work. None of the support defined above is directly related to the research described in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>10</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>10</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>4</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39376996</ArticleId><ArticleId IdType="pmc">PMC11456799</ArticleId><ArticleId IdType="doi">10.1016/j.omtn.2024.102331</ArticleId><ArticleId IdType="pii">S2162-2531(24)00218-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hu B., Guo H., Zhou P., Shi Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021;19:141–154. doi: 10.1038/s41579-020-00459-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00459-7</ArticleId><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Msemburi W., Karlinsky A., Knutson V., Aleshin-Guendel S., Chatterji S., Wakefield J. The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature. 2023;613:130–137. doi: 10.1038/s41586-022-05522-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05522-2</ArticleId><ArticleId IdType="pmc">PMC9812776</ArticleId><ArticleId IdType="pubmed">36517599</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Excess Mortality Collaborators Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet. 2022;399:1513–1536. doi: 10.1016/S0140-6736(21)02796-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02796-3</ArticleId><ArticleId IdType="pmc">PMC8912932</ArticleId><ArticleId IdType="pubmed">35279232</ArticleId></ArticleIdList></Reference><Reference><Citation>von Delft A., Hall M.D., Kwong A.D., Purcell L.A., Saikatendu K.S., Schmitz U., Tallarico J.A., Lee A.A. Accelerating antiviral drug discovery: lessons from COVID-19. Nat. Rev. Drug Discov. 2023;22:585–603. doi: 10.1038/s41573-023-00692-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-023-00692-8</ArticleId><ArticleId IdType="pmc">PMC10176316</ArticleId><ArticleId IdType="pubmed">37173515</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A.K., Mishevich J.L., Mesecar A., Mitsuya H. Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS-CoV-2 Infection and COVID-19. ChemMedChem. 2022;17 doi: 10.1002/cmdc.202200440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cmdc.202200440</ArticleId><ArticleId IdType="pmc">PMC9538661</ArticleId><ArticleId IdType="pubmed">36165855</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards A.M., Baric R.S., Saphire E.O., Ulmer J.B. Stopping pandemics before they start: Lessons learned from SARS-CoV-2. Science. 2022;375:1133–1139. doi: 10.1126/science.abn1900.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abn1900</ArticleId><ArticleId IdType="pubmed">35271333</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G., Hilgenfeld R., Whitley R., De Clercq E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat. Rev. Drug Discov. 2023;22:449–475. doi: 10.1038/s41573-023-00672-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-023-00672-y</ArticleId><ArticleId IdType="pmc">PMC10113999</ArticleId><ArticleId IdType="pubmed">37076602</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh M., de Wit E. Antiviral agents for the treatment of COVID-19: Progress and challenges. Cell Rep. Med. 2022;3 doi: 10.1016/j.xcrm.2022.100549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100549</ArticleId><ArticleId IdType="pmc">PMC8831133</ArticleId><ArticleId IdType="pubmed">35474740</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanderson T., Hisner R., Donovan-Banfield I., Hartman H., Lochen A., Peacock T.P., Ruis C. A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes. Nature. 2023;623:594–600. doi: 10.1038/s41586-023-06649-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06649-6</ArticleId><ArticleId IdType="pmc">PMC10651478</ArticleId><ArticleId IdType="pubmed">37748513</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenke K., Lewis M.C., Feldmann F., Bohrnsen E., Schwarz B., Okumura A., Bohler W.F., Callison J., Shaia C., Bosio C.M., et al. Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques. JCI Insight. 2023;8 doi: 10.1172/jci.insight.166485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.166485</ArticleId><ArticleId IdType="pmc">PMC9977490</ArticleId><ArticleId IdType="pubmed">36574296</ArticleId></ArticleIdList></Reference><Reference><Citation>Shyr Z.A., Cheng Y.S., Lo D.C., Zheng W. Drug combination therapy for emerging viral diseases. Drug Discov. Today. 2021;26:2367–2376. doi: 10.1016/j.drudis.2021.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2021.05.008</ArticleId><ArticleId IdType="pmc">PMC8139175</ArticleId><ArticleId IdType="pubmed">34023496</ArticleId></ArticleIdList></Reference><Reference><Citation>Moumne L., Marie A.C., Crouvezier N. Oligonucleotide Therapeutics: From Discovery and Development to Patentability. Pharmaceutics. 2022;14 doi: 10.3390/pharmaceutics14020260.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14020260</ArticleId><ArticleId IdType="pmc">PMC8876811</ArticleId><ArticleId IdType="pubmed">35213992</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond S.M., Aartsma-Rus A., Alves S., Borgos S.E., Buijsen R.A.M., Collin R.W.J., Covello G., Denti M.A., Desviat L.R., Echevarría L., et al. Delivery of oligonucleotide-based therapeutics: challenges and opportunities. EMBO Mol. Med. 2021;13 doi: 10.15252/emmm.202013243.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202013243</ArticleId><ArticleId IdType="pmc">PMC8033518</ArticleId><ArticleId IdType="pubmed">33821570</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul S., Caruthers M.H. Synthesis of Backbone-Modified Morpholino Oligonucleotides Using Phosphoramidite Chemistry. Molecules. 2023;28 doi: 10.3390/molecules28145380.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules28145380</ArticleId><ArticleId IdType="pmc">PMC10384400</ArticleId><ArticleId IdType="pubmed">37513252</ArticleId></ArticleIdList></Reference><Reference><Citation>Egli M., Manoharan M. Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Res. 2023;51:2529–2573. doi: 10.1093/nar/gkad067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkad067</ArticleId><ArticleId IdType="pmc">PMC10085713</ArticleId><ArticleId IdType="pubmed">36881759</ArticleId></ArticleIdList></Reference><Reference><Citation>Idris A., Supramaniam A., Tayyar Y., Kelly G., McMillan N.A.J., Morris K.V. An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity. Antivir. Res. 2024;222 doi: 10.1016/j.antiviral.2024.105815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2024.105815</ArticleId><ArticleId IdType="pubmed">38246206</ArticleId></ArticleIdList></Reference><Reference><Citation>Hariharan V.N., Shin M., Chang C.W., O'Reilly D., Biscans A., Yamada K., Guo Z., Somasundaran M., Tang Q., Monopoli K., et al. Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection. Proc. Natl. Acad. Sci. USA. 2023;120 doi: 10.1073/pnas.2219523120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2219523120</ArticleId><ArticleId IdType="pmc">PMC10089225</ArticleId><ArticleId IdType="pubmed">36893269</ArticleId></ArticleIdList></Reference><Reference><Citation>Idris A., Davis A., Supramaniam A., Acharya D., Kelly G., Tayyar Y., West N., Zhang P., McMillan C.L.D., Soemardy C., et al. A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19. Mol. Ther. 2021;29:2219–2226. doi: 10.1016/j.ymthe.2021.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2021.05.004</ArticleId><ArticleId IdType="pmc">PMC8118699</ArticleId><ArticleId IdType="pubmed">33992805</ArticleId></ArticleIdList></Reference><Reference><Citation>Vora S.M., Fontana P., Mao T., Leger V., Zhang Y., Fu T.M., Lieberman J., Gehrke L., Shi M., Wang L., et al. Targeting stem-loop 1 of the SARS-CoV-2 5' UTR to suppress viral translation and Nsp1 evasion. Proc. Natl. Acad. Sci. USA. 2022;119 doi: 10.1073/pnas.2117198119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2117198119</ArticleId><ArticleId IdType="pmc">PMC8892331</ArticleId><ArticleId IdType="pubmed">35149555</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu C., Lee J.Y., Woo J.Z., Xu L., Nguyenla X., Yamashiro L.H., Ji F., Biering S.B., Van Dis E., Gonzalez F., et al. An intranasal ASO therapeutic targeting SARS-CoV-2. Nat. Commun. 2022;13:4503. doi: 10.1038/s41467-022-32216-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32216-0</ArticleId><ArticleId IdType="pmc">PMC9349213</ArticleId><ArticleId IdType="pubmed">35922434</ArticleId></ArticleIdList></Reference><Reference><Citation>Khaitov M., Nikonova A., Kofiadi I., Shilovskiy I., Smirnov V., Elisytina O., Maerle A., Shatilov A., Shatilova A., Andreev S., et al. Treatment of COVID-19 patients with a SARS-CoV-2-specific siRNA-peptide dendrimer formulation. Allergy. 2023;78:1639–1653. doi: 10.1111/all.15663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.15663</ArticleId><ArticleId IdType="pubmed">36721963</ArticleId></ArticleIdList></Reference><Reference><Citation>Summerton J., Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 1997;7:187–195.</Citation><ArticleIdList><ArticleId IdType="pubmed">9212909</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein D., Foster E., Huang S.B., Weller D., Summerton J. A specificity comparison of four antisense types: morpholino, 2'-O-methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev. 1997;7:151–157.</Citation><ArticleIdList><ArticleId IdType="pubmed">9212905</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulton J.D. Using Morpholinos to Control Gene Expression. Curr. Protoc. Nucleic Acid Chem. 2017;68:4.30.1–4.30.29. doi: 10.1002/cpnc.21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpnc.21</ArticleId><ArticleId IdType="pmc">PMC7162182</ArticleId><ArticleId IdType="pubmed">28252184</ArticleId></ArticleIdList></Reference><Reference><Citation>Filonova G., Aartsma-Rus A. Next steps for the optimization of exon therapy for Duchenne muscular dystrophy. Expet Opin. Biol. Ther. 2023;23:133–143. doi: 10.1080/14712598.2023.2169070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14712598.2023.2169070</ArticleId><ArticleId IdType="pubmed">36655939</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts T.C., Wood M.J.A., Davies K.E. Therapeutic approaches for Duchenne muscular dystrophy. Nat. Rev. Drug Discov. 2023;22:917–934. doi: 10.1038/s41573-023-00775-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-023-00775-6</ArticleId><ArticleId IdType="pubmed">37652974</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilton-Clark H., Yokota T. Recent Trends in Antisense Therapies for Duchenne Muscular Dystrophy. Pharmaceutics. 2023;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10054484</ArticleId><ArticleId IdType="pubmed">36986639</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulton H.M., Nelson M.H., Hatlevig S.A., Reddy M.T., Iversen P.L. Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjugate Chem. 2004;15:290–299.</Citation><ArticleIdList><ArticleId IdType="pubmed">15025524</ArticleId></ArticleIdList></Reference><Reference><Citation>Deas T.S., Binduga-Gajewska I., Tilgner M., Ren P., Stein D.A., Moulton H.M., Iversen P.L., Kauffman E.B., Kramer L.D., Shi P.Y. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J. Virol. 2005;79:4599–4609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1069577</ArticleId><ArticleId IdType="pubmed">15795246</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulton H.M., Hase M.C., Smith K.M., Iversen P.L. HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev. 2003;13:31–43.</Citation><ArticleIdList><ArticleId IdType="pubmed">12691534</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall N.B., Oda S.K., London C.A., Moulton H.M., Iversen P.L., Kerkvliet N.I., Mourich D.V. Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing. J. Immunol. Methods. 2007;325:114–126.</Citation><ArticleIdList><ArticleId IdType="pubmed">17673254</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulton H.M., Moulton J.D. Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim. Biophys. Acta. 2010;1798:2296–2303.</Citation><ArticleIdList><ArticleId IdType="pubmed">20170628</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulton H.M. In vivo delivery of morpholino oligos by cell-penetrating peptides. Curr. Pharmaceut. Des. 2013;19:2963–2969.</Citation><ArticleIdList><ArticleId IdType="pubmed">23140456</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabriel G., Nordmann A., Stein D.A., Iversen P.L., Klenk H.D. Morpholino oligomers targeting the PB1 and NP genes enhance the survival of mice infected with highly pathogenic influenza A H7N7 virus. J. Gen. Virol. 2008;89:939–948.</Citation><ArticleIdList><ArticleId IdType="pubmed">18343835</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai S.H., Stein D.A., Guerrero-Plata A., Liao S.L., Ivanciuc T., Hong C., Iversen P.L., Casola A., Garofalo R.P. Inhibition of respiratory syncytial virus infections with morpholino oligomers in cell cultures and in mice. Mol. Ther. 2008;16:1120–1128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782410</ArticleId><ArticleId IdType="pubmed">18443602</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupfer C., Stein D.A., Mourich D.V., Tepper S.E., Iversen P.L., Pastey M. Inhibition of influenza A H3N8 virus infections in mice by morpholino oligomers. Arch. Virol. 2008;153:929–937. doi: 10.1007/s00705-008-0067-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-008-0067-0</ArticleId><ArticleId IdType="pubmed">18369525</ArticleId></ArticleIdList></Reference><Reference><Citation>Limburg H., Harbig A., Bestle D., Stein D.A., Moulton H.M., Jaeger J., Janga H., Hardes K., Koepke J., Schulte L., et al. TMPRSS2 Is the Major Activating Protease of Influenza A Virus in Primary Human Airway Cells and Influenza B Virus in Human Type II Pneumocytes. J. Virol. 2019;93:10–1128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6803253</ArticleId><ArticleId IdType="pubmed">31391268</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein D.A. Inhibition of RNA virus infections with peptide-conjugated morpholino oligomers. Curr. Pharmaceut. Des. 2008;14:2619–2634.</Citation><ArticleIdList><ArticleId IdType="pubmed">18991679</ArticleId></ArticleIdList></Reference><Reference><Citation>Nan Y., Zhang Y.J. Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds. Front. Microbiol. 2018;9:750. doi: 10.3389/fmicb.2018.00750.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.00750</ArticleId><ArticleId IdType="pmc">PMC5920040</ArticleId><ArticleId IdType="pubmed">29731743</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren T.K., Shurtleff A.C., Bavari S. Advanced morpholino oligomers: a novel approach to antiviral therapy. Antivir. Res. 2012;94:80–88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7114334</ArticleId><ArticleId IdType="pubmed">22353544</ArticleId></ArticleIdList></Reference><Reference><Citation>Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M., Henzler-Wildman K., Pawłowski K., Chen Z., Li Y., et al. The mechanism of RNA capping by SARS-CoV-2. Nature. 2022;609:793–800. doi: 10.1038/s41586-022-05185-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05185-z</ArticleId><ArticleId IdType="pmc">PMC9492545</ArticleId><ArticleId IdType="pubmed">35944563</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner S., Kratzel A., Barut G.T., Lang R.M., Aguiar Moreira E., Thomann L., Kelly J.N., Thiel V. SARS-CoV-2 biology and host interactions. Nat. Rev. Microbiol. 2024;22:206–225. doi: 10.1038/s41579-023-01003-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-023-01003-z</ArticleId><ArticleId IdType="pubmed">38225365</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D., Lee J.Y., Yang J.S., Kim J.W., Kim V.N., Chang H. The Architecture of SARS-CoV-2 Transcriptome. Cell. 2020;181:914–921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7179501</ArticleId><ArticleId IdType="pubmed">32330414</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma R., Saha S., Kumar S., Mani S., Maiti T.K., Surjit M. RNA-Protein Interaction Analysis of SARS-CoV-2 5' and 3' Untranslated Regions Reveals a Role of Lysosome-Associated Membrane Protein-2a during Viral Infection. mSystems. 2021;6 doi: 10.1128/mSystems.00643-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSystems.00643-21</ArticleId><ArticleId IdType="pmc">PMC8407388</ArticleId><ArticleId IdType="pubmed">34254825</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao C., Cai Z., Xiao X., Rao J., Chen J., Hu N., Yang M., Xing X., Wang Y., Li M., et al. The architecture of the SARS-CoV-2 RNA genome inside virion. Nat. Commun. 2021;12:3917. doi: 10.1038/s41467-021-22785-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-22785-x</ArticleId><ArticleId IdType="pmc">PMC8225788</ArticleId><ArticleId IdType="pubmed">34168138</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenke K., Leventhal S., Moulton H.M., Hatlevig S., Hawman D., Feldmann H., Stein D.A. Inhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino oligomers. J. Antimicrob. Chemother. 2021;76:413–417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7717290</ArticleId><ArticleId IdType="pubmed">33164048</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Born E., Stein D.A., Iversen P.L., Snijder E.J. Antiviral activity of morpholino oligomers designed to block various aspects of Equine arteritis virus amplification in cell culture. J. Gen. Virol. 2005;86:3081–3090.</Citation><ArticleIdList><ArticleId IdType="pubmed">16227231</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Stein D.A., Timoney P.J., Balasuriya U.B.R. Curing of HeLa cells persistently infected with equine arteritis virus by a peptide-conjugated morpholino oligomer. Virus Res. 2010;150:138–142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7114391</ArticleId><ArticleId IdType="pubmed">20206215</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.J., Stein D.A., Fan S.M., Wang K.Y., Kroeker A.D., Meng X.J., Iversen P.L., Matson D.O. Suppression of porcine reproductive and respiratory syndrome virus replication by morpholino antisense oligomers. Vet. Microbiol. 2006;117:117–129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7117520</ArticleId><ArticleId IdType="pubmed">16839712</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrer R., Neuman B.W., Ting J.P.C., Stein D.A., Moulton H.M., Iversen P.L., Kuhn P., Buchmeier M.J. Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models. J. Virol. 2007;81:5637–5648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1900280</ArticleId><ArticleId IdType="pubmed">17344287</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel D., Opriessnig T., Stein D.A., Halbur P.G., Meng X.J., Iversen P.L., Zhang Y.J. Peptide-conjugated morpholino oligomers inhibit porcine reproductive and respiratory syndrome virus replication. Antivir. Res. 2008;77:95–107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7114306</ArticleId><ArticleId IdType="pubmed">17959259</ArticleId></ArticleIdList></Reference><Reference><Citation>Opriessnig T., Patel D., Wang R., Halbur P.G., Meng X.J., Stein D.A., Zhang Y.J. Inhibition of porcine reproductive and respiratory syndrome virus infection in piglets by a peptide-conjugated morpholino oligomer. Antivir. Res. 2011;91:36–42.</Citation><ArticleIdList><ArticleId IdType="pubmed">21554902</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel D., Stein D.A., Zhang Y.J. Morpholino oligomer-mediated protection of porcine pulmonary alveolar macrophages from arterivirus-induced cell death. Antivir. Ther. 2009;14:899–909. doi: 10.3851/IMP1409.</Citation><ArticleIdList><ArticleId IdType="doi">10.3851/IMP1409</ArticleId><ArticleId IdType="pubmed">19918094</ArticleId></ArticleIdList></Reference><Reference><Citation>Holden K.L., Stein D.A., Pierson T.C., Ahmed A.A., Clyde K., Iversen P.L., Harris E. Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the top of the terminal 3' stem-loop structure. Virology. 2006;344:439–452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16214197</ArticleId></ArticleIdList></Reference><Reference><Citation>Paessler S., Rijnbrand R., Stein D.A., Ni H., Yun N.E., Dziuba N., Borisevich V., Seregin A., Ma Y., Blouch R., et al. Inhibition of alphavirus infection in cell culture and in mice with antisense morpholino oligomers. Virology. 2008;376:357–370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2447162</ArticleId><ArticleId IdType="pubmed">18468653</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein D.A., Huang C.Y.H., Silengo S., Amantana A., Crumley S., Blouch R.E., Iversen P.L., Kinney R.M. Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus. J. Antimicrob. Chemother. 2008;62:555–565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7109848</ArticleId><ArticleId IdType="pubmed">18567576</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein D.A., Skilling D.E., Iversen P.L., Smith A.W. Inhibition of Vesivirus infections in mammalian tissue culture with antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev. 2001;11:317–325.</Citation><ArticleIdList><ArticleId IdType="pubmed">11763348</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinney R.M., Huang C.Y.H., Rose B.C., Kroeker A.D., Dreher T.W., Iversen P.L., Stein D.A. Inhibition of dengue virus serotypes 1 to 4 in vero cell cultures with morpholino oligomers. J. Virol. 2005;79:5116–5128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1069583</ArticleId><ArticleId IdType="pubmed">15795296</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao Z., Tidu A., Eriani G., Martin F. Secondary structure of the SARS-CoV-2 5'-UTR. RNA Biol. 2021;18:447–456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7544965</ArticleId><ArticleId IdType="pubmed">32965173</ArticleId></ArticleIdList></Reference><Reference><Citation>Sosnowski P., Tidu A., Eriani G., Westhof E., Martin F. Correlated sequence signatures are present within the genomic 5'UTR RNA and NSP1 protein in coronaviruses. RNA. 2022;28:729–741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9014872</ArticleId><ArticleId IdType="pubmed">35236777</ArticleId></ArticleIdList></Reference><Reference><Citation>Wacker A., Weigand J.E., Akabayov S.R., Altincekic N., Bains J.K., Banijamali E., Binas O., Castillo-Martinez J., Cetiner E., Ceylan B., et al. Secondary structure determination of conserved SARS-CoV-2 RNA elements by NMR spectroscopy. Nucleic Acids Res. 2020;48:12415–12435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736788</ArticleId><ArticleId IdType="pubmed">33167030</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriani G., Martin F. Viral and cellular translation during SARS-CoV-2 infection. FEBS Open Bio. 2022;12:1584–1601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9110871</ArticleId><ArticleId IdType="pubmed">35429230</ArticleId></ArticleIdList></Reference><Reference><Citation>Tidu A., Janvier A., Schaeffer L., Sosnowski P., Kuhn L., Hammann P., Westhof E., Eriani G., Martin F. The viral protein NSP1 acts as a ribosome gatekeeper for shutting down host translation and fostering SARS-CoV-2 translation. RNA. 2020;27:253–264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7901841</ArticleId><ArticleId IdType="pubmed">33268501</ArticleId></ArticleIdList></Reference><Reference><Citation>Bujanic L., Shevchuk O., von Kügelgen N., Kalinina A., Ludwik K., Koppstein D., Zerna N., Sickmann A., Chekulaeva M. The key features of SARS-CoV-2 leader and NSP1 required for viral escape of NSP1-mediated repression. RNA. 2022;28:766–779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9014875</ArticleId><ArticleId IdType="pubmed">35232816</ArticleId></ArticleIdList></Reference><Reference><Citation>Swenson D.L., Warfield K.L., Warren T.K., Lovejoy C., Hassinger J.N., Ruthel G., Blouch R.E., Moulton H.M., Weller D.D., Iversen P.L., Bavari S. Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob. Agents Chemother. 2009;53:2089–2099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2681561</ArticleId><ArticleId IdType="pubmed">19223614</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebleu B., Moulton H.M., Abes R., Ivanova G.D., Abes S., Stein D.A., Iversen P.L., Arzumanov A.A., Gait M.J. Cell penetrating peptide conjugates of steric block oligonucleotides. Adv. Drug Deliv. Rev. 2008;60:517–529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7103303</ArticleId><ArticleId IdType="pubmed">18037527</ArticleId></ArticleIdList></Reference><Reference><Citation>Abes R., Moulton H.M., Clair P., Yang S.T., Abes S., Melikov K., Prevot P., Youngblood D.S., Iversen P.L., Chernomordik L.V., Lebleu B. Delivery of steric block morpholino oligomers by (R-X-R)4 peptides: structure-activity studies. Nucleic Acids Res. 2008;36:6343–6354. doi: 10.1093/nar/gkn541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkn541</ArticleId><ArticleId IdType="pmc">PMC2582615</ArticleId><ArticleId IdType="pubmed">18796528</ArticleId></ArticleIdList></Reference><Reference><Citation>Amantana A., Moulton H.M., Cate M.L., Reddy M.T., Whitehead T., Hassinger J.N., Youngblood D.S., Iversen P.L. Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjugate Chem. 2007;18:1325–1331.</Citation><ArticleIdList><ArticleId IdType="pubmed">17583927</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakowski M.A., Beutler N., Wolff K.C., Kirkpatrick M.G., Chen E., Nguyen T.T.H., Riva L., Shaabani N., Parren M., Ricketts J., et al. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. Nat. Commun. 2021;12:3309. doi: 10.1038/s41467-021-23328-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23328-0</ArticleId><ArticleId IdType="pmc">PMC8175350</ArticleId><ArticleId IdType="pubmed">34083527</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen D.R., Allerton C.M.N., Anderson A.S., Aschenbrenner L., Avery M., Berritt S., Boras B., Cardin R.D., Carlo A., Coffman K.J., et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374:1586–1593. doi: 10.1126/science.abl4784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abl4784</ArticleId><ArticleId IdType="pubmed">34726479</ArticleId></ArticleIdList></Reference><Reference><Citation>Deas T.S., Bennett C.J., Jones S.A., Tilgner M., Ren P., Behr M.J., Stein D.A., Iversen P.L., Kramer L.D., Bernard K.A., Shi P.Y. In Vitro Resistance Selection and In Vivo Efficacy of Morpholino Oligomers against West Nile Virus. Antimicrob. Agents Chemother. 2007;51:2470–2482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1913242</ArticleId><ArticleId IdType="pubmed">17485503</ArticleId></ArticleIdList></Reference><Reference><Citation>Soonthornvacharin S., Rodriguez-Frandsen A., Zhou Y., Galvez F., Huffmaster N.J., Tripathi S., Balasubramaniam V.R.M.T., Inoue A., de Castro E., Moulton H., et al. Systems-based analysis of RIG-I-dependent signalling identifies KHSRP as an inhibitor of RIG-I receptor activation. Nat. Microbiol. 2017;2:17022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5338947</ArticleId><ArticleId IdType="pubmed">28248290</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathi S., Pohl M.O., Zhou Y., Rodriguez-Frandsen A., Wang G., Stein D.A., Moulton H.M., DeJesus P., Che J., Mulder L.C.F., et al. Meta- and Orthogonal Integration of Influenza "OMICs" Data Defines a Role for UBR4 in Virus Budding. Cell Host Microbe. 2015;18:723–735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4829074</ArticleId><ArticleId IdType="pubmed">26651948</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Sancho L., Tripathi S., Rodriguez-Frandsen A., Pache L., Sanchez-Aparicio M., McGregor M.J., Haas K.M., Swaney D.L., Nguyen T.T., Mamede J.I., et al. Restriction factor compendium for influenza A virus reveals a mechanism for evasion of autophagy. Nat. Microbiol. 2021;6:1319–1333. doi: 10.1038/s41564-021-00964-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-021-00964-2</ArticleId><ArticleId IdType="pmc">PMC9683089</ArticleId><ArticleId IdType="pubmed">34556855</ArticleId></ArticleIdList></Reference><Reference><Citation>Muñoz-Fontela C., Dowling W.E., Funnell S.G.P., Gsell P.S., Riveros-Balta A.X., Albrecht R.A., Andersen H., Baric R.S., Carroll M.W., Cavaleri M., et al. Animal models for COVID-19. Nature. 2020;586:509–515. doi: 10.1038/s41586-020-2787-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2787-6</ArticleId><ArticleId IdType="pmc">PMC8136862</ArticleId><ArticleId IdType="pubmed">32967005</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler E.S., Bailey A.L., Kafai N.M., Nair S., McCune B.T., Yu J., Fox J.M., Chen R.E., Earnest J.T., Keeler S.P., et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 2020;21:1327–1335. doi: 10.1038/s41590-020-0778-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0778-2</ArticleId><ArticleId IdType="pmc">PMC7578095</ArticleId><ArticleId IdType="pubmed">32839612</ArticleId></ArticleIdList></Reference><Reference><Citation>Fumagalli V., Di Lucia P., Ravà M., Marotta D., Bono E., Grassi S., Donnici L., Cannalire R., Stefanelli I., Ferraro A., et al. Nirmatrelvir treatment of SARS-CoV-2-infected mice blunts antiviral adaptive immune responses. EMBO Mol. Med. 2023;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10165354</ArticleId><ArticleId IdType="pubmed">36946379</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Cao L., Li G., Cong F., Li Y., Sun J., Luo Y., Chen G., Li G., Wang P., et al. Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. J. Med. Chem. 2022;65:2785–2793. doi: 10.1021/acs.jmedchem.0c01929.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.0c01929</ArticleId><ArticleId IdType="pubmed">33523654</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelnabi R., Foo C.S., Kaptein S.J.F., Boudewijns R., Vangeel L., De Jonghe S., Jochmans D., Weynand B., Neyts J. A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection. J. Virol. 2022;96</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9400483</ArticleId><ArticleId IdType="pubmed">35924921</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge Q., Pastey M., Kobasa D., Puthavathana P., Lupfer C., Bestwick R.K., Iversen P.L., Chen J., Stein D.A. Inhibition of multiple subtypes of influenza a virus in cell cultures with morpholino oligomers. Antimicrob. Agents Chemother. 2006;50:3724–3733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1635187</ArticleId><ArticleId IdType="pubmed">16966399</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto S., Echigoya Y., Tago A., Segawa T., Sato Y., Itou T. Antiviral Efficacy of RNase H-Dependent Gapmer Antisense Oligonucleotides against Japanese Encephalitis Virus. Int. J. Mol. Sci. 2023;24</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10573891</ArticleId><ArticleId IdType="pubmed">37834294</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhorne-Pollet S., Fitzpatrick C., Da Costa B., Bourgon C., Eléouët J.F., Meunier N., Burzio V.A., Delmas B., Barrey E. Antisense oligonucleotides targeting ORF1b block replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Front. Microbiol. 2022;13 doi: 10.3389/fmicb.2022.915202.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2022.915202</ArticleId><ArticleId IdType="pmc">PMC9644129</ArticleId><ArticleId IdType="pubmed">36386681</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagey R.J., Elazar M., Pham E.A., Tian S., Ben-Avi L., Bernardin-Souibgui C., Yee M.F., Moreira F.R., Rabinovitch M.V., Meganck R.M., et al. Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2. Nat. Med. 2022;28:1944–1955. doi: 10.1038/s41591-022-01908-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01908-x</ArticleId><ArticleId IdType="pmc">PMC10132811</ArticleId><ArticleId IdType="pubmed">35982307</ArticleId></ArticleIdList></Reference><Reference><Citation>Lulla V., Wandel M.P., Bandyra K.J., Ulferts R., Wu M., Dendooven T., Yang X., Doyle N., Oerum S., Beale R., et al. Targeting the Conserved Stem Loop 2 Motif in the SARS-CoV-2 Genome. J. Virol. 2021;95</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8223950</ArticleId><ArticleId IdType="pubmed">33963053</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannitti T., Morales-Medina J.C., Palmieri B. Phosphorothioate oligonucleotides: effectiveness and toxicity. Curr. Drug Targets. 2014;15:663–673.</Citation><ArticleIdList><ArticleId IdType="pubmed">24655142</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferdinandi E.S., Vassilakos A., Lee Y., Lightfoot J., Fitsialos D., Wright J.A., Young A.H. Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2. Cancer Chemother. Pharmacol. 2011;68:193–205. doi: 10.1007/s00280-010-1473-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00280-010-1473-z</ArticleId><ArticleId IdType="pubmed">20886212</ArticleId></ArticleIdList></Reference><Reference><Citation>Flynn L.L., Li R., Pitout I.L., Aung-Htut M.T., Larcher L.M., Cooper J.A.L., Greer K.L., Hubbard A., Griffiths L., Bond C.S., et al. Single Stranded Fully Modified-Phosphorothioate Oligonucleotides can Induce Structured Nuclear Inclusions, Alter Nuclear Protein Localization and Disturb the Transcriptome In Vitro. Front. Genet. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9019733</ArticleId><ArticleId IdType="pubmed">35464859</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawicki S.G., Sawicki D.L., Siddell S.G. A contemporary view of coronavirus transcription. J. Virol. 2007;81:20–29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1797243</ArticleId><ArticleId IdType="pubmed">16928755</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q., Ponty Y., Will S., et al. The SARS-CoV-2 subgenome landscape and its novel regulatory features. Mol. Cell. 2021;81:2135–2147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7927579</ArticleId><ArticleId IdType="pubmed">33713597</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone B., Urakova N., Snijder E.J., Campbell E.A. Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design. Nat. Rev. Mol. Cell Biol. 2022;23:21–39. doi: 10.1038/s41580-021-00432-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00432-z</ArticleId><ArticleId IdType="pmc">PMC8613731</ArticleId><ArticleId IdType="pubmed">34824452</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinton M.A., Basu M. Functions of the 3' and 5' genome RNA regions of members of the genus Flavivirus. Virus Res. 2015;206:108–119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4540327</ArticleId><ArticleId IdType="pubmed">25683510</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhugiri R., Karl N., Petersen D., Lamkiewicz K., Fricke M., Wend U., Scheuer R., Marz M., Ziebuhr J. Structural and functional conservation of cis-acting RNA elements in coronavirus 5'-terminal genome regions. Virology. 2018;517:44–55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112051</ArticleId><ArticleId IdType="pubmed">29223446</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang D., Leibowitz J.L. The structure and functions of coronavirus genomic 3' and 5' ends. Virus Res. 2015;206:120–133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4476908</ArticleId><ArticleId IdType="pubmed">25736566</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziv O., Price J., Shalamova L., Kamenova T., Goodfellow I., Weber F., Miska E.A. The Short- and Long-Range RNA-RNA Interactome of SARS-CoV-2. Mol. Cell. 2020;80:1067–1077.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7643667</ArticleId><ArticleId IdType="pubmed">33259809</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyde J.L., Chen R., Trobaugh D.W., Diamond M.S., Weaver S.C., Klimstra W.B., Wilusz J. The 5' and 3' ends of alphavirus RNAs--Non-coding is not non-functional. Virus Res. 2015;206:99–107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4654126</ArticleId><ArticleId IdType="pubmed">25630058</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuman B.W., Stein D.A., Kroeker A.D., Churchill M.J., Kim A.M., Kuhn P., Dawson P., Moulton H.M., Bestwick R.K., Iversen P.L., Buchmeier M.J. Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers. J. Virol. 2005;79:9665–9676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1181598</ArticleId><ArticleId IdType="pubmed">16014928</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P., Faraone J.N., Hsu C.C., Chamblee M., Zheng Y.M., Carlin C., Bednash J.S., Horowitz J.C., Mallampalli R.K., Saif L.J., et al. Neutralization escape, infectivity, and membrane fusion of JN.1-derived SARS-CoV-2 SLip, FLiRT, and KP.2 variants. Cell Rep. 2024;43 doi: 10.1016/j.celrep.2024.114520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2024.114520</ArticleId><ArticleId IdType="pmc">PMC11430188</ArticleId><ArticleId IdType="pubmed">39024099</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Li Y., Liu Q., Yao Q., Wang X., Zhang H., Chen R., Ren L., Min J., Deng F., et al. SARS-CoV-2 cell tropism and multiorgan infection. Cell Discov. 2021;7:17. doi: 10.1038/s41421-021-00249-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-021-00249-2</ArticleId><ArticleId IdType="pmc">PMC7987126</ArticleId><ArticleId IdType="pubmed">33758165</ArticleId></ArticleIdList></Reference><Reference><Citation>Bösmüller H., Matter M., Fend F., Tzankov A. The pulmonary pathology of COVID-19. Virchows Arch. 2021;478:137–150. doi: 10.1007/s00428-021-03053-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00428-021-03053-1</ArticleId><ArticleId IdType="pmc">PMC7892326</ArticleId><ArticleId IdType="pubmed">33604758</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamers M.M., Haagmans B.L. SARS-CoV-2 pathogenesis. Nat. Rev. Microbiol. 2022;20:270–284. doi: 10.1038/s41579-022-00713-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00713-0</ArticleId><ArticleId IdType="pubmed">35354968</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryce C., Grimes Z., Pujadas E., Ahuja S., Beasley M.B., Albrecht R., Hernandez T., Stock A., Zhao Z., AlRasheed M.R., et al. Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. Mod. Pathol. 2021;34:1456–1467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8015313</ArticleId><ArticleId IdType="pubmed">33795830</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao F., Ma Q., Yue Q., Chen H. SARS-CoV-2 Infection and Lung Regeneration. Clin. Microbiol. Rev. 2022;35</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8809385</ArticleId><ArticleId IdType="pubmed">35107300</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruge C.A., Kirch J., Lehr C.M. Pulmonary drug delivery: from generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges. Lancet Respir. Med. 2013;1:402–413. doi: 10.1016/S2213-2600(13)70072-70079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(13)70072-70079</ArticleId><ArticleId IdType="pubmed">24429205</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickey A.J. Back to the future: inhaled drug products. J. Pharmacol. Sci. (Tokyo, Jpn.) 2013;102:1165–1172. doi: 10.1002/jps.23465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.23465</ArticleId><ArticleId IdType="pubmed">23381932</ArticleId></ArticleIdList></Reference><Reference><Citation>Forbes B., Asgharian B., Dailey L.A., Ferguson D., Gerde P., Gumbleton M., Gustavsson L., Hardy C., Hassall D., Jones R., et al. Challenges in inhaled product development and opportunities for open innovation. Adv. Drug Deliv. Rev. 2011;63:69–87. doi: 10.1016/j.addr.2010.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2010.11.004</ArticleId><ArticleId IdType="pubmed">21144875</ArticleId></ArticleIdList></Reference><Reference><Citation>Abes S., Moulton H.M., Clair P., Prevot P., Youngblood D.S., Wu R.P., Iversen P.L., Lebleu B. Vectorization of morpholino oligomers by the (R-Ahx-R)(4) peptide allows efficient splicing correction in the absence of endosomolytic agents. J. Contr. Release. 2006;116:304–313.</Citation><ArticleIdList><ArticleId IdType="pubmed">17097177</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y.F. End-Modifications on Morpholino Oligos. Methods Mol. Biol. 2017;1565:39–50. doi: 10.1007/978-1-4939-6817-6_4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-6817-6_4</ArticleId><ArticleId IdType="pubmed">28364232</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Ma L., Zou D., Zhang R., Bai X., Li L., Wu G., Huang T., Zhao W., Jin E., et al. RCoV19: A One-stop Hub for SARS-CoV-2 Genome Data Integration, Variant Monitoring, and Risk Pre-warning. Dev. Reprod. Biol. 2023;21:1066–1079. doi: 10.1016/j.gpb.2023.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gpb.2023.10.004</ArticleId><ArticleId IdType="pmc">PMC10928372</ArticleId><ArticleId IdType="pubmed">37898309</ArticleId></ArticleIdList></Reference><Reference><Citation>Members C.-N., Partners Database Resources of the National Genomics Data Center, China National Center for Bioinformation in 2024. Nucleic Acids Res. 2024;52:D18–D32. doi: 10.1093/nar/gkad1078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkad1078</ArticleId><ArticleId IdType="pmc">PMC10767964</ArticleId><ArticleId IdType="pubmed">38018256</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao Y., Xue Y. From BIG Data Center to China National Center for Bioinformation. Dev. Reprod. Biol. 2023;21:900–903. doi: 10.1016/j.gpb.2023.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gpb.2023.10.001</ArticleId><ArticleId IdType="pmc">PMC10928365</ArticleId><ArticleId IdType="pubmed">37832784</ArticleId></ArticleIdList></Reference><Reference><Citation>Edgar R.C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004;32:1792–1797. doi: 10.1093/nar/gkh340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkh340</ArticleId><ArticleId IdType="pmc">PMC390337</ArticleId><ArticleId IdType="pubmed">15034147</ArticleId></ArticleIdList></Reference><Reference><Citation>Levengood J.D., Rollins C., Mishler C.H.J., Johnson C.A., Miner G., Rajan P., Znosko B.M., Tolbert B.S. Solution structure of the HIV-1 exon splicing silencer 3. J. Mol. Biol. 2012;415:680–698. doi: 10.1016/j.jmb.2011.11.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2011.11.034</ArticleId><ArticleId IdType="pubmed">22154809</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo L., Chiu L.Y., Sugarman A., Gupta P., Rouskin S., Tolbert B.S. HnRNP A1/A2 Proteins Assemble onto 7SK snRNA via Context Dependent Interactions. J. Mol. Biol. 2021;433 doi: 10.1016/j.jmb.2021.166885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2021.166885</ArticleId><ArticleId IdType="pmc">PMC8091503</ArticleId><ArticleId IdType="pubmed">33684393</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahl A., Gralinski L.E., Johnson C.E., Yao W., Kovarova M., Dinnon K.H., 3rd, Liu H., Madden V.J., Krzystek H.M., De C., White K.K. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature. 2021;591:451–457. doi: 10.1038/s41586-021-03312-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03312-w</ArticleId><ArticleId IdType="pmc">PMC7979515</ArticleId><ArticleId IdType="pubmed">33561864</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao L., Deng W., Huang B., Gao H., Liu J., Ren L., Wei Q., Yu P., Xu Y., Qi F., et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020;583:830–833. doi: 10.1038/s41586-020-2312-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2312-y</ArticleId><ArticleId IdType="pubmed">32380511</ArticleId></ArticleIdList></Reference><Reference><Citation>Case J.B., Bailey A.L., Kim A.S., Chen R.E., Diamond M.S. Growth, detection, quantification, and inactivation of SARS-CoV-2. Virology. 2020;548:39–48. doi: 10.1016/j.virol.2020.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2020.05.015</ArticleId><ArticleId IdType="pmc">PMC7293183</ArticleId><ArticleId IdType="pubmed">32838945</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A., Bhat P., Ollikainen N., Quinodoz S.A., Loney C., et al. SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host Defenses. Cell. 2020;183:1325–1339. doi: 10.1016/j.cell.2020.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.004</ArticleId><ArticleId IdType="pmc">PMC7543886</ArticleId><ArticleId IdType="pubmed">33080218</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>